ArriVent BioPharma Inc
Veridion Score
Composite trend over time
Why is AVBP moving today?
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AVBP.
AVBP insider activity
ArriVent BioPharma Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$13.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-03 | 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | Insider | sell | $23.37 | 555,555 | 3,929,117 | $13.0M | SEC Form 4 |
| 2025-07-15 | 2025-07-11 | LaChapelle Robin | Insider | buy | $2.28 | 6,503 | 135,736 | $15K | SEC Form 4 |
| 2025-07-15 | 2025-07-11 | LaChapelle Robin | Insider | buy | $2.28 | 2,600 | 129,233 | $6K | SEC Form 4 |
| 2025-07-15 | 2025-07-11 | LaChapelle Robin | Insider | buy | $2.28 | 2,050 | 126,633 | $5K | SEC Form 4 |
AVBP contract awards, year to date.
Public federal awards linked to this ticker.
AVBP lobbying filings, year to date.
Registered lobbying filings matched to ArriVent BioPharma Inc.